Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-03-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: kidneybreast cancerchemotherapystagetransplantation
  Phrases that lowered it: efficacygroupuppercooperativeevaluate the
• Sponsor's past termination rate: 3.8% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 152 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 312 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 23.9% (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Maximum age: 65 (lowers risk) · Who can join
• Drug's FAERS reports before start: 103347 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) NCT02685111 · started 2016 · scored riskier than 70% of active trials terminated
• Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer NCT05283616 · started 2017 · scored riskier than 30% of active trials completed
• Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients NCT03376503 · started 2016 · scored riskier than 25% of active trials completed
• SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) NCT02643420 · started 2016 · scored riskier than 60% of active trials completed
• SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide NCT02953340 · started 2017 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.